Efficacy and safety of chemotherapy (CT) ± pertuzumab (P) for platinum-resistant ovarian cancer (PROC): AGO-OVAR 2.20/ENGOT-ov14/PENELOPE double-blind placebo-controlled randomized phase III trial.
2015 ◽
Vol 33
(15_suppl)
◽
pp. 5504-5504
◽
Keyword(s):
Keyword(s):
Keyword(s):
2016 ◽
Vol 18
(5)
◽
pp. 528-532
◽
Keyword(s):
Keyword(s):
Keyword(s):
Keyword(s):